Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > LATEST
LATEST
-
BUSINESS Fuji Inks Deal with Daiichi on Ranmark Biosimilar, Now Plans 2026 Launch
November 4, 2025
-
REGULATORY Anticoagulants and Other Drugs under PMDA Safety Review
November 4, 2025
-
BUSINESS Otsuka Snags APAC Rights to 4DMT’s AMD Gene Therapy
November 4, 2025
-
REGULATORY Health Minister Vows to Balance Public Burden, Innovation, and Supply in FY2026 Revision
October 31, 2025
-
BUSINESS Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
October 31, 2025
-
BUSINESS Boehringer Bags Rights to Kyowa Kirin’s Preclinical Autoimmune Program
October 31, 2025
-
BUSINESS Espha’s Velcade AG Wins Approval for Mantle Cell Lymphoma
October 31, 2025
-
BUSINESS MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
-
BUSINESS Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
-
BUSINESS Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
October 31, 2025
-
BUSINESS Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
-
BUSINESS Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
-
REGULATORY LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
-
REGULATORY Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
-
BUSINESS Leqembi’s April-September Sales at 41.1 Billion Yen: Eisai
October 31, 2025
-
BUSINESS TMS Founder Sees “Ray of Hope” in Novel Stroke Drug TMS-007
October 31, 2025
-
COLUMN The Unseen Edge & the Shadow of Bias: Awareness as the Cornerstone of Leadership Success
October 31, 2025
-
BUSINESS Jardiance Dominates September Detailing Rankings with Five Wins: Intage
October 31, 2025
-
REGULATORY Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
October 30, 2025
-
REGULATORY Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
October 30, 2025
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…